Evolus, Inc. (EOLS) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Evolus, Inc. (EOLS) stock forecast summary
Our AI ranks Evolus, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Evolus, Inc. is a small-cap company with a market capitalization of $512M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for EOLS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, EOLS included.
Follow EOLS freeEOLS price chart and AI forecast
How EOLS ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Evolus, Inc. (EOLS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | EOLS | Rank |
|---|---|---|
| Market Cap | $512M | 60/60 |
| EPS | $-0.65 | – |
| Revenue/Share | $4.79 | – |
| FCF/Share | $-0.28 | – |
Profitability & Margins
| Metric | EOLS | Rank |
|---|---|---|
| ROA | -13.8% | 25/39 |
| ROIC | -12.5% | 25/41 |
| Gross Margin | 66.7% | 22/29 |
| Operating Margin | -5.9% | 18/33 |
| Net Margin | -10.8% | 21/33 |
| EBT Margin | -10.6% | 26/40 |
| Tax Rate | -1.9% | – |
Financial Health
| Metric | EOLS | Rank |
|---|---|---|
| Current Ratio | 1.70x | 39/50 |
| Quick Ratio | 1.28x | 27/37 |
| Interest Coverage | -1.3x | 22/36 |
| Working Capital | $69M | 48/50 |
Cash Flow
| Metric | EOLS | Rank |
|---|---|---|
| Operating Cash Flow | -$15M | 28/49 |
| Free Cash Flow | -$18M | 23/39 |
| Capital Spending | -$3M | 12/39 |
| FCF/Sales | -5.8% | 24/34 |
| CapEx/Sales | 0.9% | 25/34 |
Operational Efficiency
| Metric | EOLS | Rank |
|---|---|---|
| Asset Turnover | 1.28x | 3/38 |
| Receivables Turnover | 5.1x | 19/34 |
| Inventory Turnover | 2.6x | 7/27 |
| Fixed Assets Turnover | 62.7x | 11/37 |
| Days Sales Outstanding | 72 days | 16/34 |
| Days Inventory | 142 days | 21/27 |
| Payables Period | 154 days | 13/23 |
| Cash Conversion Cycle | 60 days | 15/21 |
Income Statement
| Metric | EOLS | Rank |
|---|---|---|
| Total Revenue | $316M | 32/39 |
| Operating Income | -$18M | 19/41 |
| Net Income | -$34M | 20/40 |
| R&D Expense | $10M | 48/48 |
| SG&A Expense | $216M | 32/35 |
| Cost of Goods Sold | $105M | 20/27 |
Dividend & Shareholder Information
| Metric | EOLS | Rank |
|---|---|---|
| Shares Outstanding | 66M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $168M | 67.6% of assets |
| Cash & Short-term Investments | $45M | 18.2% of assets |
| Accounts Receivable | $62M | 25.2% of assets |
| Inventory | $41M | 16.5% of assets |
| Total Liabilities | $279M | 112.5% of assets |
| Short-term Debt | $54M | 21.9% of assets |
EOLS quarterly financials and insider trading
Evolus, Inc. (EOLS) industry peers
Companies classified under the same SEC industry code as Evolus, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| EOLS Evolus, Inc. | ▲ | $512M |
| LLY Eli Lilly & Co | ▶ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.83B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▼ | $178.73B |
| PFE Pfizer Inc | ▶ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $122.98B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▶ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $30.70B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.01B |
| ZLAB Zai Lab Ltd | ▶ | $25.93B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.31B |
| INSM Insmed Inc | ▼ | $21.14B |
| VTRS Viatris Inc | ▶ | $19.81B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▲ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.79B |
| ABVX Abivax S.A. | ▼ | $6.77B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▲ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where EOLS sits on the market map
Evolus, Inc. (EOLS) stock news
Loading...
Evolus, Inc. (EOLS) stock forecast FAQ
What is the Evolus, Inc. (EOLS) stock forecast?
Our AI ranks Evolus, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Evolus, Inc. stock predictions?
A per-ticker accuracy statistic for EOLS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Evolus, Inc. forecasts updated?
Evolus, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Evolus, Inc.'s industry peers?
60 issuers in our coverage, EOLS included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.